Skip to main content
. 2016 Jan 15;81(2):235–245. doi: 10.1111/bcp.12787

Table 2.

Geometric mean ratios and 90% confidence intervals (CIs) for comparison of oral capsule and intravenous (i.v.) formulation of ibrutinib, with and without food (treatment B vs. treatment A), and with and without grapefruit juice (treatment C vs. treatment B)

Parameter* Test treatment/reference treatment N Geometric mean Ratio: test/reference (%) 90% CI (%) Intraparticipant CV (%)
Oral (treatment B vs. treatment A: with vs. without food)
Cmax (ng ml–1) B 8 121 352 (213, 582) 62
A 8 34
AUClast (ng h ml–1) B 8 588 223 (167, 297) 31
A 8 264
AUC (ng h ml–1) B 4 677 187 (137, 256) 19
A 4 362
i.v. (treatment B vs. treatment A: with vs. without food
B 8 5032 81 (37, 176) 99
Cmax (pg ml–1) A 8 6255
B 8 1380 85 (72, 100) 18
AUClast (pg h ml–1) A 8 1631
B 6 1329 82 (68, 100) 17
AUC (pg h ml–1) A 6 1612
Oral (treatment C vs. treatment B: with vs. without GFJ)
Cmax (ng ml–1) C 8 437 360 (269, 483) 31
B 8 121
AUClast (ng h ml–1) C 8 1236 210 (182, 243) 15
B 8 588
AUC (ng h ml–1) C 7 1378 215 (184, 250) 14
B 7 643
i.v. (treatment C vs. treatment B: with vs. without GFJ)
Cmax (pg ml–1) C 8 5903 117 (58, 238) 84
B 8 5032
AUClast (pg h ml–1) C 8 1401 102 (89, 116) 14
B 8 1380
AUC (pg h ml–1) C 7 1416 104 (90, 120) 13
B 7 1363

AUC, area under the plasma concentration–time curve from time zero to infinite time, calculated as the sum of AUClast and Clastz; AUClast, area under the plasma concentration–time curve from time zero to the time of the last quantifiable concentration; Cmax, maximum plasma concentration; CV, coefficient of variation.

*

A mixed‐effects model with treatment as a fixed effect and subject as a random effect was used for analysis on a log scale and the results were presented at original scale after antilogarithmic transformation.